%0 Journal Article
%T Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression
%A David Z Chang
%A Ying Ma
%A Baoan Ji
%A Yan Liu
%A Patrick Hwu
%A James L Abbruzzese
%A Craig Logsdon
%A Huamin Wang
%J Journal of Hematology & Oncology
%D 2012
%I BioMed Central
%R 10.1186/1756-8722-5-15
%X We compared CDC20 expression levels in normal, cancerous, and inflamed pancreatic tissues from stage II PDAC patients with clinical outcomes and determined CDC20 levels in seven PDAC cell lines. CDC20 was identified using a cDNA microarray database containing gene expression profiles for PDAC tissues and cell lines and chronic pancreatitis and normal pancreas tissues. Its expression was confirmed by real-time quantitative reverse-transcriptase-polymerase chain reaction (qRT-PCR). An immunohistochemical analysis of tissue microarrays from resected PDAC tumors and paired benign pancreatic tissues was done and CDC20 levels were correlated with clinical outcome.Fifty-six patients were included in this study. A microarray analysis revealed 5-fold higher CDC20 expression in PDAC tissue than in chronic pancreatitis tissue. A qRT-PCR analysis confirmed a mean 20-fold higher CDC20 level in PDAC tissue than in normal pancreas and pancreatitis tissue. RNA and protein CDC20 expression was detected in several PDAC cell lines. An immunohistochemical analysis revealed higher CDC20 protein expression levels in PDAC tissue than in normal pancreas tissue, and high CDC20 expression was associated with poor differentiation (P = 0.020) and a significantly lower 5-year recurrence-free survival rate (P = 0.039); we also found a trend toward a shorter overall survival duration.Aberrant CDC20 expression may play an important role in PDAC tumorigenesis and progression and may thus be useful as a marker of disease progression and prognosis and as a therapeutic target.Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death in the United States [1]: the annual number of associated deaths is similar to the disease's annual incidence [2]. Similar statistics are reported from other countries. For example, a recent evaluation of the Finnish Cancer Registry, which recorded 4922 patients with pancreatic cancer between 1990 and 1996, revealed that only 89 (1.8%) had survive
%K CDC20
%K Pancreatic cancer
%K Tumorigenesis
%K Progression
%K Prognosis
%U http://www.jhoonline.org/content/5/1/15